Chimagen Biosciences
PrivateLast Round
M&A
Oct 29, 2024
Company Overview
Chimagen Biosciences is a clinical-stage biotechnology company that discovers and develops multi-specific T cell-engagers and NK cell-engagers for the treatment of cancer and autoimmune diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Chimagen Biosciences Comparables
Compare Chimagen Biosciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Innovent Biologics | 82% | |
| Harbour BioMed | 79% | |
| AstraZeneca | 78% | |
Chimagen Biosciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| M&A | Oct 29, 2024 | ||||
| Series B | Oct 1, 2024 |
Chimagen Biosciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Foresite Capital | Series B |
| Lilly Asia Ventures | Series B |
Chimagen Biosciences Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Chimagen Biosciences's valuation, stock price, and market status.